Moderate to Severe Rheumatoid Arthritis Market Outlook & Forecast: Precision Medicine Shifts | Thelansis

As the RA treatment paradigm shifts from trial-and-error escalation toward precision-driven immunomodulation, Thelansis delivers a definitive 10-year intelligence report covering 31 markets globally.
Thelansis has released its comprehensive Moderate to Severe Rheumatoid Arthritis - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (2026-2036). The report arrives at an inflection point for the RA market, one defined by landmark guideline updates, a rapidly evolving pipeline, and growing clinical urgency to address the large share of patients still failing current therapies.

Executive Summary
Rheumatoid Arthritis remains one of the most commercially significant autoimmune indications globally. The global RA drug market, valued at approximately USD 27-28 billion in 2025, is projected to reach USD 40-50 billion by 2035, driven by rising disease prevalence, biologics innovation, biosimilar competition reshaping market dynamics, and accelerating adoption in Asia-Pacific markets.

What has changed and what makes 2026 a pivotal year - is context. In March 2026, EULAR published its 2025 update to RA management recommendations, the most significant guideline revision since 2022. The updated framework now explicitly positions biologics as the preferred first advanced therapy after csDMARD failure, with JAK inhibitors recommended only following careful individual cardiovascular and malignancy risk assessment. This is already reshaping prescribing behavior across the G8 markets and creating new commercial headroom for well-differentiated emerging therapies.
At the same time, the biosimilar wave for key TNF inhibitors continues, compressing revenues for established brands and accelerating the search for next-generation mechanisms.

The Thelansis report covers all of this, from patient-level epidemiology and drug-treated populations across G8 countries to brand-level market share forecasts, pipeline assessments, and KOL-validated unmet need insights.

Request a Free Sample of the Moderate to Severe Rheumatoid Arthritis - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2026 To 2036: https://thelansis.com/reports/moderate-to-severe-rheumatoid-arthritis-market-outlook-forecast-2026-to-2036/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=msrd_mo

Key Emerging Players & Pipeline Momentum
The RA pipeline is meaningfully active, with novel mechanisms entering later-stage development alongside reformulations and device innovations from established players.
Notable pipeline developments shaping the 2026-2036 forecast horizon:
● Eli Lilly / Incyte - Baricitinib (approved JAK1/2 inhibitor) continues to expand its evidence base; combination strategies with TNF inhibitors in development
● AbbVie - Upadacitinib (selective JAK1) remains a significant growth driver; additional combination work with adalimumab ongoing in clinical studies
● Bristol-Myers Squibb - Abatacept lifecycle programs and combination approaches with methotrexate and adalimumab in Phase III
● Celltrion - CT-P13 SC Auto-Injector advancing biosimilar convenience formulations
● AstraZeneca - AZD1163, a novel mechanism candidate, in Phase II evaluation
● Roche - Afimkibart in Phase II; targeting novel immune pathways
● BeiGene - BGB-45035 entering Phase II, signaling deepening Chinese pharma investment in autoimmune indications
● Lynk Pharmaceuticals - Zemprocitinib (LNK01001), a selective JAK inhibitor, reported statistically significant Phase III results in January 2026 with a favorable tolerability profile
Artiva Biotherapeutics - AlloNK received FDA Fast Track Designation in October 2025 for refractory RA in combination with rituximab, the first cell therapy to achieve this status in the indication
The pipeline signals a clear strategic bifurcation: established players optimizing existing mechanisms while emerging entrants push into genuinely novel MoAs, a dynamic Thelansis report maps in detail across development stages.

Download a Sample of the Moderate to Severe Rheumatoid Arthritis Market Outlook and Forecast Report 2026-2036 to Review Emerging Therapies and Market Epidemiology: https://thelansis.com/reports/moderate-to-severe-rheumatoid-arthritis-market-outlook-forecast-2026-to-2036/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=msrd_mo

Key Current Therapies & Standard of Care
The RA treatment landscape is well-established but increasingly stratified. Conventional synthetic DMARDs, primarily methotrexate, remain the first-line anchor. When disease activity persists, the standard moves to targeted therapies:
● Biologic DMARDs (bDMARDs): TNF inhibitors (adalimumab, etanercept, certolizumab, golimumab, infliximab) remain the dominant class by patient share, though biosimilar entry has significantly eroded brand-level revenues for the originator products. IL-6 inhibitors (tocilizumab, sarilumab) and the T-cell costimulation blocker abatacept represent established second- and third-line options.
● JAK Inhibitors (tsDMARDs): Tofacitinib, baricitinib, and upadacitinib have reshaped the oral treatment landscape. However, post-marketing safety signals, elevated risks of MACE, thrombosis, and malignancy flagged by the ORAL Surveillance trial, have prompted label updates and more cautious prescribing. The 2025 EULAR update now formally recommends JAK inhibitors only after careful individual risk stratification, affecting prescribing patterns particularly in older or high-risk patient segments.
● Biosimilars: Patent expirations for key biologics between 2026 and 2028 are expected to intensify biosimilar competition further, compressing pricing and creating opportunities for differentiated molecules with superior convenience, safety, or efficacy profiles.
The Thelansis report includes granular drug utilization data, prescription share analysis by line of therapy, and KOL-perceived advantages and disadvantages for each key therapy across the G8 markets.

Discover More About Therapies Set To Grab Major Moderate to Severe Rheumatoid Arthritis Market Share: https://thelansis.com/reports/moderate-to-severe-rheumatoid-arthritis-market-outlook-forecast-2026-to-2036/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=msrd_mo

Key Market Drivers & Trends
Several converging forces are shaping the RA market through 2036:
● Precision Medicine Is Moving from Aspiration to Practice: The 2025 EULAR guidelines reinforce individual risk-based therapy selection. Combined with growing evidence on cytokine profiling and molecular signatures, the market is edging toward biomarker-guided prescribing, a trend that will reward drug developers who can define clear patient subpopulations.
● Biosimilar Penetration Accelerates Market Restructuring: With multiple originator TNF inhibitor patents expiring between 2026 and 2028, biosimilars will exert downward pricing pressure while potentially expanding treatment access in cost-sensitive markets. This dynamic creates both a risk (for incumbent brands) and an opportunity (for premium-positioned differentiated therapies).
● Asia-Pacific Is the Fastest-Growing Geography: Japan, China, South Korea, and emerging Southeast Asian markets are seeing rising diagnosed prevalence, expanding reimbursement coverage, and increasing physician willingness to prescribe advanced therapies. Novartis's Q1 2025 launch of Cosentyx for RA in Japan underscores the commercial momentum in this region.
● Patient-Centric Formulations Are Gaining Ground: Subcutaneous auto-injectors, long-acting formulations, and eventually oral alternatives to injectables are becoming key differentiation levers as more therapies compete for the same patient pools.
● BMS's USD 500 Million Autoimmune Research Investment (Q2 2025) signals that large pharma continues to view autoimmune inflammation, with RA at the center, as a decade-defining therapeutic priority.

Key Unmet Needs & KOL Expectations
Despite a crowded market, significant clinical gaps remain. KOL interviews conducted by Thelansis in 2025-26 across rheumatologists, immunologists, and clinical researchers reveal consistent themes:
1. No Pathway to Drug-Free Sustained Remission Current therapies control disease but rarely achieve durable, treatment-free remission. Most patients require lifelong therapy and experience periodic flares. KOLs are prioritizing immune-reset and tolerogenic approaches for the next generation of development candidates.
2. 30-40% of Patients Fail or Lose Response A substantial portion of patients show inadequate response or secondary failure to TNF inhibitors, IL-6 inhibitors, or JAK inhibitors. Cycling remains common. KOLs are looking for novel mechanisms such as, GM-CSF antagonists, BTK inhibitors, bispecifics, that work specifically in refractory or multi-line failure populations.
3. Safety Concerns Are Constraining Prescribing JAK inhibitor safety signals have created real-world prescribing hesitancy beyond guideline caution. KOLs consistently express the need for therapies with cleaner long-term safety profiles, particularly lower infection risk, reduced thrombosis signals, and absence of malignancy concerns.
4. Delayed Diagnosis & Trial-and-Error Escalation Treatment still follows a step-up escalation model that delays optimal therapy access. Precision medicine approaches with early predictive tools remain a top-cited unmet need, particularly tools that can stratify patients at first presentation.
5. No Validated Predictive Biomarkers Clinical decisions rely heavily on empirical switching. KOLs see biomarker-driven treatment algorithms covering response prediction, remission likelihood, and flare risk as the single largest gap between current practice and optimal RA care.

These insights, along with detailed Target Product Profile (TPP) expectations and therapy-specific opportunity assessment, are available in full within the Thelansis report.

Review the complete Moderate to Severe Rheumatoid Arthritis KOL survey findings and unmet need analysis: https://thelansis.com/reports/moderate-to-severe-rheumatoid-arthritis-market-outlook-forecast-2026-to-2036/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=msrd_mo

CONTACT:
Himanshi Negi
Manager - Global BD, and Partnering
Thelansis Knowledge Partners
Email: n.himanshi@thelansis.com
Phone: +91-9560149525
Website: www.thelansis.com
Reach us at: clientsupport@thelansis.com

ABOUT THELANSIS:
Thelansis is a global healthcare market intelligence company providing strategic insights to global pharmaceutical, biotechnology, and life sciences organizations. Through proprietary epidemiology models, primary research, physician interviews, payer analysis, and commercial forecasting, Thelansis enables organizations to make informed decisions across product development, market access, and commercialization.

In addition, Thelansis offers EpiLansis, an AI-powered cloud intelligence platform that enables interactive exploration of patient populations, epidemiology trends, treatment utilization, and market dynamics across multiple therapeutic areas.

For more information about Thelansis and its disease intelligence solutions, visit our website or contact our team.

This release was published on openPR.